What Does Androgen Receptor Signaling Pathway in Sertoli Cells During Normal Spermatogenesis Tell Us?

Jia-Ming Wang†, Zhen-Fang Li† and Wan-Xi Yang*

The Sperm Laboratory, College of Life Sciences, Zhejiang University, Hangzhou, China

Androgen receptor signaling pathway is necessary to complete spermatogenesis in testes. Difference between androgen binding location in Sertoli cell classifies androgen receptor signaling pathway into classical signaling pathway and non-classical signaling pathway. As the only somatic cell type in seminiferous tubule, Sertoli cells are under androgen receptor signaling pathway regulation via androgen receptor located in cytoplasm and plasma membrane. Androgen receptor signaling pathway is able to regulate biological processes in Sertoli cells as well as germ cells surrounded between Sertoli cells. Our review will summarize the major discoveries of androgen receptor signaling pathway in Sertoli cells and the paracrine action on germ cells. Androgen receptor signaling pathway regulates Sertoli cell proliferation and maturation, as well as maintain the integrity of blood-testis barrier formed between Sertoli cells. Also, Spermatogonia stem cells achieve a balance between self-renewal and differentiation under androgen receptor signaling regulation. Meiotic and post-meiotic processes including Sertoli cell - Spermatid attachment and Spermatid development are guaranteed by androgen receptor signaling until the final sperm release. This review also includes one disease related to androgen receptor signaling dysfunction named as androgen insensitivity syndrome. As a step further ahead, this review may be conducive to develop therapies which can cure impaired androgen receptor signaling in Sertoli cells.

Keywords: androgen receptor, Sertoli cell, signaling pathway, spermatogenesis, androgen insensitivity syndrome

1 INTRODUCTION

Male infertility is currently a major problem worldwide and causes substantial psychological and social distress (1). It not only puts a huge economic burden on patients, but also poses a great challenge to the health-care system. Male infertility is due to abnormal sperm parameters in the male partner and contributes to 50% of all cases of infertility, highlighting the importance of normal spermatogenesis (2, 3).
Spermatogenesis is a complex process that is under precise regulation. Starting from spermatogonia stem cell (SSC) producing differentiated spermatogonia, spermatogonia transform into spermatocytes which then undergo meiotic divisions to produce round spermatids (4). Round spermatids undergo cytodifferentiation to form spermatozoa, which are ultimately released to the lumen (5).

As the only somatic cell type in seminiferous tubules (6), Sertoli cells (SCs) make normal spermatogenesis possible by providing the nutrition necessary for the development of germ cells (7), forming blood-testis barrier (BTB) between SCs in mammalian testes (8, 9), attaching to germ cells (GCs) through adherens junctions (10) and phagocytosing apoptotic GCs for recycling (11). SCs function like a nurse to take good care of spermatogenesis (12). These functions of SCs are regulated by both extrinsic and intrinsic factors. The former factors include hormone and paracrine molecules and the latter include genomic regulators. Here, we review androgen receptor (AR) signaling pathway in SCs, a pathway that provides an excellent example of a combination of extrinsic and intrinsic regulation. AR begins its expression 3-5 days after birth in rodent testis while AR expression begins about 5 months after birth in men (13, 14). In men, its expression in SCs peaks during stage III of the six stages (15). AR signaling pathway can be classified into classical signaling pathway and non-classical signaling pathway with different functions and different efficiencies. It has been shown that abnormal AR signaling can impair spermatogenesis (16).

Although decades of studies have brought us a better understanding of AR signaling in spermatogenesis using altered testosterone signaling model, Sertoli cell androgen receptor knockout model, specificity-affecting androgen receptor knockin model as well as Ribo-Tag mouse model, not enough information has been gained to lift the veil of its beauty. As a result, it is necessary to review current work about androgen receptor signaling pathway in SCs and put forward suggestions for future studies. Ultimately, all of our hard work aims to achieve “bench to bedside” translation that can be used to develop therapies for illnesses related to hormone dysfunction.

We surveyed articles in the PubMed database using the following search terms: androgen receptor*, Sertoli cell*, spermatogonia*, maturation and differentiation*, spermatogenesis*, meiosis*, spermatid* and androgen-insensitive syndrome*. The gene encoding AR is located on the X chromosome, belonging to nuclear receptor subfamily 3, group C, member 4. It consists of 8 exons that encode 4 domains: an N-terminal domain (exon 1), a DNA-binding domain (exon 2 and exon 3), a hinge region that contains the nuclear localization signal (exon 3 and exon 4) and a ligand-binding domain (exons 4-8) (17, 18).

The N-terminal domain contains activation function domain-1 which is constitutively active (15). The DNA-binding domain contains two zinc fingers to complex with its hormone response element, where each of them is coordinated by four cysteines. One zinc finger is involved in direct DNA binding mediated by the P(proximal) box, which recognizes the specific hormone response element half-site 5′-AGAACA-3′. The other zinc finger is involved in a “head-to-head” receptor dimerization through the D(istal) box (19–22). The hinge region contains the nuclear localization signal which is essential for nuclear import. Residues from the major nuclear localization signal site 629-RKLLK-634 contribute to importinβ binding (23–25). Then the ligand-binding domain consists of 11 α-helices and two small, two-stranded β-sheets arranged in a typical three-layer antiparallel helical sandwich fold (26, 27). Binding of androgen to ligand-binding domain can activate the receptor. Both of these structures are important for androgen receptor function, though the structure of full-length androgen receptor has not been solved yet.

3 OVERVIEW OF ANDROGEN RECEPTOR SIGNALING PATHWAY IN SERTOLI CELLS

In adult rodent testes, the AR expression level in SCs is low except during stage VI-VIII of the seminiferous epithelium (28). In men, its expression in SCs peaks during stage III of the six stages (29). This stage-specific peak of AR expression in SCs is coordinated with initiation of testosterone-dependent processes that is essential for spermatogenesis such as appearance of preleptotene spermatocytes and the initiation of meiosis during stages VII–VIII, as confirmed by Sertoli cell androgen receptor knock out model and androgen receptor knock out model (5). It is reasonable that AR signaling in SCs mediates paracrine action on germ cells and autocrine action on themselves to form a microenvironment for meiosis completion.

Stimulated by luteinizing hormone in the pituitary gland which is part of the hypothalamus-pituitary-gonadal axis, Leydig cells produce androgen. When androgen saturates the AR of SCs and binds to AR, the AR signaling pathway is activated (30). Testosterone is the most abundant androgen produced in the testis. Another important androgen is dihydrotestosterone (DHT), which is produced by peripheral tissues where 5α-reductases reduce testosterone to DHT (31, 32). When hormone levels in the targeted tissue are low, DHT is more potent than testosterone due to its higher binding affinity for AR. When the testosterone level in the testis is high, there are no differences between testosterone and DHT (33). Testosterone concentrations in the testes of men (340–2000 nM) are 25 to 125-fold greater than those in serum (8.75–35 mM), similar to the situation in rodent testes (5). The testosterone level needed to maintain spermatogenesis is approximately 10-25% of the intratesticular testosterone level (34). AR signaling pathway in
FIGURE 1 | Classical and non-classical AR signaling pathways in SCs. The SC shown on the left illustrates the classical signaling pathway, while the SC shown on the right illustrates the non-classical signaling pathway (both classical and non-classical signaling pathways can exist in a single SC; the two pathways are presented in separate cells for simplicity). Between the two neighboring SCs are germ cells (spermatogonia stem cells, spermatogonia, primary spermatocytes, secondary spermatocytes, spermatids and spermatozoa). SCs function as a nurse to take good care of normal spermatogenesis as spermatogonia stem cells develop into spermatozoa in the lumen. Androgen secreted by Leydig cells diffuses through the plasma membrane and binds to the AR complex in the cytoplasm to activate the classical signaling pathway. The AR then detaches from the HSP complex and enters the nucleus to form AR dimers. Dimerized ARs bind to the AREs of their target genes and thereby regulate their transcription. The classical signaling pathway can promote SC maturation, induce SSC differentiation, guarantee spermatocyte meiosis, and ensure BTB integrity. The non-classical signaling pathway begins with translocation of the AR from the cytoplasm to the plasma membrane. There, the AR interacts with Src and causes it to phosphorylate EGFR, and this in turn activates MAPK kinases to regulate targeted gene transcription. The non-classical signaling pathway can regulate processes including BTB integrity, spermatocyte meiosis, Sertoli cell-Spermatid adhesion, spermatid development and sperm release. The three orange ovals in the figure represent the BTB, and the two black lines represent cell-cell adhesion. TF is short for transcription factor. Areas for which controversy exists are not included in the figure but are discussed in the article.
SCs can be divided into classical signaling pathway and non-classical signaling pathway. The main differences between them lie in androgen binding location and response speed. Androgen binds to cytoplasmic AR in classical signaling pathway while in non-classical signaling pathway androgen binds to AR on plasma membrane. Compared with non-classical pathway, classical pathway requires more time to show transcriptional activity change after androgen binding to androgen receptor (35).

### 3.1 Classical Signaling Pathway

Before binding to androgen, AR in the cytoplasm binds to chaperones and cochaperones, such as heat shock proteins (HSP) HSP23, HSP40, HSP56, HSP70, HSP90 via its ligand-binding domain (17). When androgen in the cytoplasm binds to AR, AR detaches from chaperone and cochaperone protein complexes and exposes its ligand-binding domain (23, 24, 36). With the help of importins, the AR monomer transits into the nucleus, where 2 AR monomers dimerize to create AR homodimers. AR homodimers then bind to androgen response elements for other transcription factor (39, 40). However, the binding sites for AR homodimers are not restricted to AREs; AR homodimers can also bind to some response elements other than transcription factor (39, 40). Notably, the classical AR signaling is relatively slow, usually 30-45 minutes is needed to induce activation or suppression of transcription, not considering the time required for protein synthesis and secretion (35).

### 3.2 Non-Classical Signaling Pathway

To date, three types of non-classical signaling pathway have been identified in the testsis. Here is the first type, as well as the main type. When the intratesticular testosterone level is relatively low (10-250 nM), testosterone binds to the AR located in the cell membrane and activates the non-classical AR signaling pathway within 1 minute (41). In the TM4 Sertoli cell line, the transport of cytoplasmic ARs to the membrane is facilitated by caveolin-1 (42). Testosterone binds to membrane AR which then interacts with the SH3 domain of SRC proto-oncogene (Src). Src then phosphorylates the epidermal growth factor receptor (EGFR) which activates Ras kinase. This activates MAPK cascade (Ras-Raf-MEK-ERK). Phosphorylated ERK can phosphorylate ribosomal protein S6 kinase A1(p90RSK). Activated p90RSK translocate into nucleus, where it activates transcription factors such as cAMP-response element-binding protein (CREB), which binds to the cAMP-response element (CRE) of the targeted gene to regulate transcription (41, 43).

An in vitro study in which the TM4 cell line was exposed to testosterone levels of 10-100 nM demonstrated that testosterone can also activate a second non-classical signaling pathway, the phosphatidylinositol 3 kinase (PI3K)/Akt pathway, directly by activating the PI3K subunit p85α. Phosphorylated Akt can activate Src and this facilitates the translocation of cytoplasmic AR to the plasma membrane (44). In addition to these in vitro studies, some in vivo studies also showed that testosterone can activate the non-classical signaling pathway in SCs (35, 45).

Another type of non-classical signaling pathway has only been found in immature Sertoli cells. Testosterone causes depolarization of Sertoli cells within thirty seconds due to closed K⁺<sub>ATP</sub> channel. This close is caused by G protein-mediated activation of phospholipase C. This action results in a rapid influx of Ca²⁺ and the activation of signaling molecules (46-48).

Recently, Zrt- and Irt-like protein 9 (ZIP9), a novel membrane-bound androgen receptor unrelated to classic AR, was found in the 93RS2 Sertoli cell line which has no cytoplasmic AR. ZIP9 participates in the phosphorylation of CREB and ATF1 via ERK1/2 to induce the expression of claudin proteins that are components of BTB. The relationship between AR signaling and ZIP9 signaling remains to be researched in the future (49).

### 4 ANDROGEN RECEPTOR SIGNALING PATHWAY IN SERTOLI CELLS CAN REGULATE SPERMATOGENESIS

#### 4.1 Role of AR Mediated Signaling in Sertoli Cell Proliferation and Maturation

SC proliferation occurs during fetal and early neonatal life in rodents, and in the fetal and peripubertal periods in higher primates when SCs undergo mitosis to increase their number (50). During the end of neonatal period or prepubertal period, SC proliferation stops. Then SCs maturation begins during puberty period, switching from an immature, proliferate state to a mature, non-proliferate state during which SCs establish BTB and acquire the ability to sustain spermatogenesis (51) AR signaling can participate in SC maturation process. Although it remains to be investigated if AR signaling in SCs influences SC proliferation, we still review studies in this field (Figure 2).

#### 4.1.1 Sertoli Cell Proliferation

According to our knowledge, final testis size, number of germ cells and sperm output are closely connected to the number of SCs. This emphasizes the significance of SC proliferation. When porcine testis was treated with AR antagonists during postnatal proliferation, an increased number of SCs per testis was detected (52). However, SC numbers were increased in young ram lambs following prenatal exposure to testosterone (53). This is not contradictory, because administration of exogenous testosterone increases negative hypothalamic feedback and may reduce intratesticular testosterone levels, leading to decreased androgen signaling. However, when comparing the number of SCs per testis in Sertoli cell androgen receptor knockout (SCARKO) mice and androgen receptor knockout (ARKO) mice with the control group, researchers found that the SCARKO mice did not show significant differences compared to the controls, whereas the ARKO mice showed a significant decrease in SC number, indicating that in mice AR in SCs has little impact on SCs proliferation (54, 55). A similar
phenomenon was found when researchers used a testicular feminization mouse (Tfm) model that lacks functional AR in all cells (56). It is difficult to reconcile these results. We think that the expression of AR in SCs is undetectable or very weak during most of the periods in which these cells proliferate. While AR on other cell types such as peritubular myoid cells, which express AR at relatively high level, may contribute to SC proliferation. Hu et al. recently found that AR could interact directly with PI3K regulatory subunit p85α to activate kinase Akt and that this represses the expression of Cytokeratin 18 (CK18) (a marker of immature and dysfunctional SCs) and induces the expression of Ki67 (a marker of SC proliferation), thereby preserving SC proliferation in mice (57). Since the experiments were conducted on mature mice, additional experiments on prepubertal mice are needed to test this result, although it is true that some immature SCs are present in mature mice. Considering these results as a whole, it seems that role of AR signaling in SC proliferation is species-specific and phase-specific. We suggest that future studies test different species with the aims of understanding and combining their AR expression patterns in SCs, their intratesticular androgen levels and their SC proliferation patterns to provide a better understanding of the role of AR in SC proliferation.

4.1.2 Sertoli Cell Maturation
Followed by cessation of SC proliferation comes to SC maturation. Around SC maturation, AR expression level is progressively upregulated until all SCs express AR (58). AR in SCs is key mediator for SC molecular and cytoskeleton maturation (59–61).

In molecular level, several molecules important for maturation are under AR signaling regulation (56). Among them, Anti Mullerian hormone (AMH) has been widely researched. AMH is crucial for fetal sex differentiation by regressing the Mullerian ducts in male (13, 63). Secreted by immature SCs, AMH has become a biomarker for testicular function in males during the prepubertal period which is tightly regulated by AR (64). During the postnatal period, AMH level can be maintained by androgen epi-testosterone through non-classical AR signaling pathway when intracellular AR level is very low (65). Other transcription factors, such as sex determining region Y-box 9 (SOX9), steroidogenic factor 1 (SF1) can bind to their own response elements to promote Amh transcription (66). Around the onset of puberty, upregulation of AR expression downregulates AMH expression by blocking SF1 binding to its response elements or interacting with SF1 response elements to
prevent SF1 from exerting a stimulatory effect on Amh transcription (67). An in vitro study using TM4 Sertoli cells and C3H10T1/2 cell line demonstrated that AR could downregulate AMH expression by repressing SOX9, consistent with the findings in the azoosperma patients and mice in vivo (68).

Besides molecular level, AR signaling is necessary for SC cytoskeleton maturation. In SCARKO mice, relatively normal SCs nuclei were displaced from the basal basement and dispersed throughout the seminiferous tubules, probably resulting from the disrupted position of vimentin and the presence of thicker basal lamina, both of which participate in the linkage between nuclei and the cell membrane (69). Another group observed that SC nuclei formed one or two layered rings located in the center of tubule in mice in which AR function had been ablated (70). Suppressed expression of connexin 43 (Cx43) in mice resulted in an intermediate state of SCs between proliferation and maturation, along with weaker AR immunostaining (71). The impaired SCs maturation observed in this model probably resulted from disrupted AR function. AR can also regulate microtubular composition and structure in SC so as to yield proper SC shape via Class III b tubulin (TUBB3) in mice and rats through classical signaling pathway (72).

Premature expression of ARs in postnatal mouse SCs resulted in fewer SCs, although GCs development accelerated in a gain-of-function mouse model (73). When the AR transgene was injected into a prenatal mouse model, precocious maturation of SCs occurred and limited the window for SC proliferation. The production of fewer SCs can lead to lower-than-normal sperm output (74).

4.1.3 Factors Regulating Androgen Receptor Mediated Sertoli Cell Proliferation and Maturation
Precise regulation of Smad2/Smad3 is important both for SC proliferation and SC maturation (72). Type II A activin promotes immature testis growth along with timely appropriate AR expression via Smad3. The expression of Smad3 is then downregulated, and this is associated with cessation of SC proliferation and progression of the cells to terminal differentiation. AR activation can induce Smad2 transcription, which will further promote SC maturation through shifting from using Smad3 only to using both Smad2 and Smad3 under activin A activation. In Smad3−/− mice, delayed maturation of SCs was accompanied by reduced levels of AR and Smad2 (75).

In recent years, microRNAs (miRNAs) have been found to regulate SC proliferation and maturation. miR-124a binds to the 3'-UTR of Ar mRNA and downregulate AR expression, thereby inhibiting the proliferation of immature porcine SCs, while the coactivator really interesting new gene (RING) finger protein 4 (RNF4) binds to AR and promotes porcine SCs proliferation by elevating Proliferation cell nuclear antigen (a marker of cell proliferation) mRNA transcript levels (76). miR-762 promotes porcine SC maturation by inhibiting binding of RNF4 to AR (77). Moreover, miR-130a has been shown to inhibit AR expression, although its impact on SC proliferation and maturation remains to be elucidated (78). Additionally, the relationship of miR-133b (79) and miR-638 (80), which regulate SC proliferation and maturation, to AR remains to be investigated (Figure 2).

Importantly, the relationship between SC maturation and spermatogenesis is not well understood. We hypothesize that AR-regulated lipid metabolism in mature SCs can provide energy for spermatogenesis (81); for example, AR signaling in SCs induces the expression of ubiquitin-conjugating enzyme E2B (Ube2b) which regulates the expression of genes related to glycosylphosphatidylinositol (GPI)-anchor biosynthesis and oxidative phosphorylation (82). So does AR-regulated glucose uptake. The non-classical pathway participates in the regulation of glucose uptake via the cytochrome C oxidase (83). Also, BTB formed between SCs can facilitate normal spermatogenesis, as we will discuss later.

4.2 Role of AR Mediated Signaling in Spermatogonia Stem Cells Self-Renewal and Differentiation
Following the migration of gonocytes to the basement membrane and their differentiation into spermatogonia stem cells (5), SSCs are influenced by a network of signaling that can trigger SSC self-renewal and differentiation. AR signaling in SCs has been found to participate in these two processes, probably promoting SSC differentiation and repressing SSC self-renewal, although it is not clear whether both of classical and non-classical signaling in SCs contribute to these processes in all species (Figure 3).

4.2.1 Wnt5a
Wnt5a, which refers to Wingless-type MMTV Integration Site Family Member 5A, is secreted by SCs in mice. Several studies found that Wnt5a expression is regulated by androgen and that it promotes SSCs self-renewal. Both in vitro and in vivo studies confirmed that Wnt5a can increase SSC self-renewal division after androgen blockage in mice SCs (84). In addition, Crespo et al. found that in zebrafish one androgen, 11-ketotestosterone (11-KT), indirectly inhibits SSC self-renewal by inhibiting prostaglandin E2 (PGE2) in SCs. Otherwise, PGE2 promotes SSC self-renewal by upregulating Wnt5a expression (85). However, more investigations should focus on the existence of AREs within the promoter of Wnt5a to confirm the exact signaling pathway in SCs through which androgen exerts its effects.

4.2.2 Plzf
Promyelocytic leukemia zinc finger (Plzf), a key transcription suppressor gene, has been characterized as a marker for undifferentiated SSCs in rodents (86) and primates (87). Plzf is important for SSC maintenance (45). Recently, in vivo and in vitro studies found that after activation of AR signaling in SCs, AR homodimer binds to the ARE region of GATA binding protein 2 (GATA-2) to inhibit its expression; this can further decrease WT1 transcription factor (WT1) expression since WT1 expression requires binding of GATA-2 to its promoter. WT1 binds to β1-integrin and increases its expression in SCs; β1-integrin will interact with unknown molecules on the surface of
SSCs, to induce Plzf expression. As a result, activation of classical AR signaling pathway can promote SSC differentiation by downregulating Plzf. However, the precise pathway between AR and Wnt5a remains unknown. Testosterone can also induce the expression of Igf3 through a non-classical signaling pathway to promote SSC differentiation. Downregulation of Wnt5a can also protect GCs from apoptosis (shown in brown). Also, AR signaling in SCs can inhibit UCHL1 expression in spermatocytes to prevent them from apoptosis (shown in brown). In addition, the clearance of apoptotic cells is also important. Testosterone inhibits mir-471-5p and thereby upregulates the expression of Dock1, ATG12, BECN1 and TFCPR1, resulting in clearance by SCs (shown in red). Esm1 upregulation by AR dimerization can also promote this process (shown in red). During spermiogenesis and spermatiation, non-classical signaling induces the expression of testin, which is needed for proper adherence junctions (AJ) dynamics (purple solid line). The residual body from the maturing sperm will be absorbed by the concerted action of Stx5a, Picalm and Eea1 (shown in green). AR dimers also bind to the coactivator Src1 to induce the expression of Stx5a and to the corepressor NCoR1 to repress the expression of Picalm and Eea1. Spermatid development is also regulated by AR signaling. AR signaling in SCs induce GRTTH and PMCA4 transcription and expression which will promote their development and motility respectively (shown in blue line). Sperm release is facilitated by Src-mediated molecular processes (indicated by the purple dotted line). ‘?’ indicates an unknown pathway.

4.3 Role of AR Mediated Signaling in Spermatocytes Meiosis

In diploid organisms, the sexual differentiation requires the production of haploid gametes via meiosis, a process in which two consecutive cell divisions occur after a round of DNA replication (93). During prophase I of meiosis, leptotene and zygotene stages produce the DNA double strand breaks (DSBs) needed for DNA recombination, along with the chiasmata required for homologous chromosome separation. Following the zygotene stage is pachytene stage, in which the synapsis is completed, and DNA combination is finished as well as DSBs repair. In SCs, the AR signaling pathway is believed to be important in these stages (94) (Figure 3).

Loss of spermatocytes and spermatids in rodents occurred as a result of decreased intratesticular testosterone level in hypophysectomy, gonadotropin-releasing hormone antagonist treatments and hypogonadal (hpg) models (95). Above results indicate that testosterone mediated AR signaling is necessary for normal meiosis. Furthermore, inhibition of AR-Src interaction...
resulted in inactivation of non-classical signaling pathway in mice. Arrested meiosis was observed at the first spermatogenic wave (45). Moreover, in SCARKO mice where classical signaling pathway is blocked, De et al. observed loss of primary spermatocytes during stages VI-VII, a time when AR shows high protein expression level (96). These results suggest that both classical and non-classical AR signaling in SCs are indispensable for normal meiosis (Figure 3). In their attempt to determine the precise process that is regulated by AR signaling, Su et al. found that in SCARKO mice, meiosis arrest occurred in prophase I; cells failed to divide, and spermatocytes failed to acquire competence for the meiotic division phase (97). Although meiosis appeared to progress to a mid-pachytene-like cytological state, most germ cells stalled at an early-pachytene transcriptome stage (98). Precisely, meiosis arrest occurred between leptotene/zygotene to early-mid pachytene transition.

We conclude that there are two causes of meiotic arrest: chromosomal dysfunction and germ cell apoptosis.

### 4.3.1 Chromosomal Dysfunction

The fact that AR expression peaks at stages VI-VIII of meiosis, coinciding with the preleptotene and leptotene stages, suggests that the AR might mediate the preparation of SCs for chromosomal synapsis and recombination. Male germ cells can enter prophase I of meiosis normally and undergo normal DSBs formation in the absence of AR signaling (5). However, the problems happened on DSBs repair and chromosome synapsis. In SCARKO mice, chromosome synapsis was incomplete, as shown by the fact that Chen et al. detected a significantly larger number of univalent chromosomes in spermatocytes than in the control group. Additionally, RAD51 and DMC1 which are required for resolution of DSBs and homologous recombination, along with TEX15, BRCA1, BRCA2 and PALB2 which load RAD51 and DMC1 onto DSBs sites, showed decreased protein expression in SCARKO mice. Furthermore, activation of AR can negatively regulate Epidermal growth factors (EGFs), including Egf, betacellulin (Btc) and neuregulin 1 (Nrg1). These EGFs bind to their corresponding receptors (EGFR, ERBB4) on the surface of spermatocytes and stimulate the accumulation of above homologous recombination factors for appropriate prophase preparation (94). At the synaptonemal complex, nuclear autoantigenic sperm protein (NASP) inhibits formation of CDC2/cyclinB1 complex via HSP70-2 which are important for G2/M transition. NASP showed elevated expression after androgen manipulation. Other genes that show changes in transcript after androgen manipulation, such as Mapre1, Rabbl1, Tubal1c, Tubal3a and Tubb2c, are related to spindle dynamics and the formation of dynactin complexes (99). Although fewer spermatocytes may gain competence to enter metaphase I, they cannot complete meiosis due to the lack of normal spindle dynamics, and this may account for the disruption in post-meiotic differentiation. More proteins account for chromosome synapsis and dynamics that is under AR regulation deserve to be confirmed to establish the AR downstream signaling network by taking advantage of the development of proteomics.

### 4.3.2 Germ Cell Apoptosis

GC apoptosis, especially apoptosis of spermatocytes, is another cause of meiotic arrest. This is not difficult to understand, since spermatocytes are cells that undergo meiosis. Through single cell transcript analysis technology, genes related to apoptosis have been identified. Aldh1a1, Igfbps, and mitochondrial membrane and oxidative phosphorylation transcripts were upregulated in SCARKO mice (98). Another group found that androgen deprivation led to a decreased expression of Aldh2, Prdx6 and Gstm5, which encode protectors of oxidative stress (99). Other genes related to androgen-dependent apoptosis, such as Diablo, Cbl, Hsf1 showed increased expression in mice after androgen deprivation or knocking out AR in SCs (97, 100). Hu et al. showed that Rhox5 can repress expression of Unc-5 Netrin Receptor C(UNC5C) which can promote spermatocyte apoptosis in vitro (101). Since Rhox5 is regulated by classical signaling pathway (90, 102, 103), it needs to be determined whether AR signaling represses UNC5C expression and thereby protects spermatocytes from apoptosis. Recently, Marina et al. found that ubiquitin carboxyl-terminal hydrolase L1(UCHL1) is negatively regulated by androgen. Decreased level of androgen leads to increased level of UCHL1 in spermatocytes, which will lead to deubiquitination of the pro-apoptotic factor p53. Deubiquitination of p53 triggers germ cell death (104). In addition, phagocytic clearance of apoptotic germ cells by SCs is vital for meiosis because phagocytosis of dying GCs provides lipid sources for SCs which will provide ATP for GCs development. Lower androgen increases the expression of miR-471-5p, resulting in inhibition of Dock1, Tecpr1, Atg12 and Becn1. This leads to impaired LC3-associated phagocytosis. Besides, inhibition of Dock1, Rac1-GTPase in this model leads to disrupted engulfment of SCs (11). Both of these inhibitions impair clearance of apoptotic GCs by SCs. Another protein Elmo1, which is upregulated by classical AR signaling in vivo, participates in apoptotic germ cells clearance by SCs and functions downstream of Dock1 and Rac1-GTPase (73, 105).

Many of the transcription factors and regulators related to AR signaling that have been found are not mentioned here. These factors can participate in the regulation of meiosis. For additional information on these factors, please see Table 1. For additional genes that show changes in expression after androgen manipulation, please see the supplied references (98, 99, 123).

Based on the evidences presented above, we propose the reasons for meiotic arrest when AR signaling in SC is impaired. Chromosomal dysfunction or breakage can induce oxidative stress that cannot be repressed because of the decreased level of oxidative stress protectors. This leads to apoptosis of some spermatocytes. The presence of increased number of apoptotic cells, the failure to clear apoptotic cells combined with DNA damage trigger the inner meiotic checkpoint and cause meiosis to halt in prophase I. Future studies might focus on the roles of genes related to AR signaling that have been mined through mRNA transcript analysis in meiosis and attempt to determine whether they play permissive roles or instructive roles for meiosis.
4.4 Role of AR Mediated Signaling in Maintenance of Blood-Testis Barrier

SCs in mammalian testis can divide the seminiferous epithelium into basal and adluminal compartments through the construction of BTB. During stages VII-VIII of seminiferous epithelium cycle when the AR expression level peaks in rodents, BTB undergoes restructuring to facilitate the translocation of preleptotene spermatocytes from the basal area to the apical area where they will complete the entire processes of meiosis and post-meiotic processes. This transition, facilitated by testosterone, requires breakage of the ‘old’ BTB before preleptotene spermatocytes and formation of ‘new’ BTB after preleptotene spermatocytes entering into adluminal compartment (97, 124). Moreover, BTB shields haploid germ cells from recognition by the innate immune system; and this is why we also call it ‘immune barrier’ (125). BTB includes many types of junctions: tight junctions (TJs), gap junctions (GJs), desmosomes, basal ectoplasmic specialization (ES). These junctions undergo dynamic changes to fulfill their roles. Exposure of SC cultures to adenovirus constructs expressing inhibitors of either classical or non-classical AR signaling pathway led to increased permeability of BTB, suggesting that both classical and non-classical signaling pathway are important for BTB integrity, probably through regulating junction proteins (45, 126). (Figure 2).

4.4.1 Tight Junction

Classical signaling pathway regulates proper tight junction dynamic. In mouse models with mutations in exon1 of AR, increased permeability of BTB was observed (124, 127).
Although the BTB appears to be present in this model under microscopic examination, it is incomplete as we found biotin enter into adluminal area with the help of biotin tracer (127). Reversibly, BTB were strengthened after testosterone treatment of an SC culture system with disrupted AR function (128). To further investigate the molecular basis of these effects, microarray analysis was used to identify the genes that may be involved. The mRNA transcript level of tight junction proteins including Claudin 3, Claudin 11, Claudin 13 were all downregulated while Occludin and Claudin 26 showed elevated transcript levels after ablation of exon1 of AR in mice (129). Among them, Claudin 3 which is not essential for fertility, is expressed in the newly formed BTB after preleptotene spermatocytes migrate past the old BTB (127). Claudin 13 shows a similar expression pattern to Claudin 3. CHIP-seq assays found putative AREs in the promoter regions of Claudin 13 and tight junction protein 2 isoform 3, indicating a potential classical signaling regulation pattern. In contrast to Claudin 3, Claudin 11 preserves its expression throughout the seminiferous cycle. Besides, membrane-associated GUK family of proteins including tight junction protein 1, tight junction protein 2 isoform 1, tight junction protein 2 isoform 2, and tight junction protein 2 isoform 3, can function as a bridge that links tight junction proteins to the cytoskeleton like actin filaments. Their mRNA transcripts were found to be downregulated in mouse SCs after ablation of AR (129-131). What’s more, it was found that tight junction proteins can enter the nuclei of SCs and regulate their own transcription (132), indicating possible tight junction proteins compensatory effects in Cldn3/- mutant mice.

Apart from its directly regulation of TJ proteins, non-classical signaling can regulate TJ proteins via tissue type plasminogen activator (tPA) during stages VII-VIII of spermatogenesis when BTB undergoes restructuring (133). We also know that tPA is involved in BTB degradation (134), indicating a potential role of tPA in BTB dynamics. Moreover, Dietze et al. and Bulldan et al. found that Claudin 1, Claudin 5 and Claudin 11 protein levels were upregulated by CREB protein (49, 135, 136). These results further support the idea that non-classical androgen signaling can maintain BTB integrity by regulating tight junction dynamics.

Besides, in heat-treated monkey testes, AR regulates reversible changes in BTB integrity via Par complex (Par6-Par3, Par6-aPKC, and Par6-Cdc42) targeting TJ proteins (ZO-1 and occludin) and basal ES proteins (N-cadherin, E-cadherin, α-catenin, β-catenin, and γ-catenin) (137).

Based on the results described above, we hypothesize that although the transition of preleptotene spermatocytes into adluminal compartment is not blocked when AR signaling in SC is prevented, the amount of claudin available for remodeling BTB (Claudin 3, Claudin 11, Claudin 13) is insufficient under these conditions. Besides, the downregulated tight junction proteins are not sufficient to enter the nucleus and increase their own transcription, let alone to recruit more claudins to the BTB. While Occludin and Claudin26 show relatively upregulated mRNA transcript levels, this is not enough to compensate for the loss of other tight junction proteins. Thus, humoral immunity against self-antigens is mounted, resulting in disruption of normal spermatogenesis.

4.4.2 Gap Junction
Connexin 43 (Cx43), one gap junction protein, also under AR regulation as shown by its reduced mRNA transcript levels and protein expression levels in adult pig testes treated with flutamide, an anti-androgen (138). Interestingly, we also found weak AR immunostaining and partial disruption of AR signaling in SCs in Sertoli cell specific knock-out of connexin 43 mice (71). Xia et al. found that androgen can regulate the expression of Wt1 indirectly by inhibiting GATA-2 expression. Androgen inhibits GATA-2 expression through the classical pathway. Wt1 can bind to the promoter of Cx43 and inhibit its expression, indicating that androgen can promote Cx43 expression by downregulating GATA-2 and Wt1 (139). What’s more, ouabain binding to its receptor ATP1A1 can upregulate Cx43 expression via non-classical signaling pathway in vivo (140). The relationship between Cx43 and AR deserves further investigation. It remains to be determined whether reversing one of them (Cx43 or AR) can restore the other to normal level in human and correct impaired spermatogenesis, though it is possible that treating hpg mice with DHT can restore the expression and localization of Cx43 to the BTB (141).

4.4.3 Blood-Testis Barrier Renewal
The endocytosis of old BTB proteins for renewal is also important for BTB integrity (142). Testosterone can promote the endocytosed occludin to the BTB location through recycling pathway (124). Other cells such as Madin-Darby canine kidney cells and epithelial cells can internalize occluding and claudin via clathrin- and caveolin-mediated pathways (143, 144). Coincidently, Su et al. found that testosterone increases levels of clathrin and caveolin-1 in SCs (145), this suggests that AR signaling may participate in tight junction protein endocytosis for renewal via the clathrin and caveolin-1 pathways. This possibility needs further investigation.

Since AR signaling is important for BTB integrity, what will happen if AR is overexpressed under normal conditions? The influence of a tighter BTB on spermatogenesis remains unknown. We suggest an in vitro AR overexpression experiment to answer this question. Recently, in muscle cells, it was found that AR can participate in IGF-1/IGF-1R-Pi3K/Akt-mTOR pathway (146). We also know that mTOR signaling can regulate BTB dynamic by balancing the levels of F-actin binding proteins epidermal growth factor receptor pathway substrate 8 and actin related protein 3 (147). Therefore, we suggest investigation into crosstalk between AR and mTOR pathway and its downstream molecules related to actin-binding proteins in germ cell lines.

4.5 Role of AR Mediated Signaling in Sertoli Cell - Spermatid Adhesion and Sperm Release
Before spermiogenesis occurs, round spermatids are linked to SCs by desmosomes. When the cycle of seminiferous epithelium
enters into stage VII, the round spermatids begin to elongate accompanied by the replacement of desmosome anchors with new specialized adhering proteins. We call the structure formed in this way as apical ectoplasmic specialization (ES). The proteins that form ES disassemble before sperm release during stage VIII. The complexes connecting SC and elongated spermatids are tubulobulbar complex and the focal adhesion-related disengagement complex. AR signaling pathway is important in two processes during spermiogenesis and final spermiation: Sertoli cell – Spermatid adhesion and sperm release (Figures 2, 3).

The importance of AR signaling in Sertoli cell - Spermatid adhesion and sperm release is elucidated by two in vivo model. First, in rats that received subdermal testosterone and oestriadiol (TE) implants to lower the intratesticular testosterone level, researchers found loss of stage VIII and late spermatids (148, 149). Additionally, hypomorphic SCARKO mice displayed premature release of round spermatids as well as blockage of terminal differentiation and release of elongated spermatids. The unreleased mature spermatids were degenerated or phagocytized by SCs (149, 150).

4.5.1 Sertoli Cell - Spermatid Adhesion

The molecular mechanism through which Sertoli cell - Spermatid adhesion occurs has been elucidated. Based on experiments in which adenovirus constructs were used to express different AR mutants that impair the classical or nonclassical pathways and on other experiments in which inhibitors of ERK kinase and Src kinase were added to an SC-GC coculture system, it is proposed by study that non-classical AR signaling pathway contributes dominantly to Sertoli cell-Spermatid adhesion, while activation of the classical AR signaling pathway is not sufficient to permit Spermatid binding to SCs (151). Testosterone can promote the attachment of spermatids to SCs in Sertoli cell - Spermatid coculture system by activation ERK and Src, which belong to the non-classical signaling pathway (152). Terada et al. found that testin, which can be induced by non-classical signaling pathway, is important for Sertoli cell - Spermatid adhesion. Overexpression of testin can block spermatid differentiation, probably due to excessive adhesion to SCs (113). However, an in vivo study adopting TE implants brought about not only the loss of spermatids but also the activation of ERK before sperm release, along with breakage association of N-cadherin and β-catenin indicating disruption of ES (153). This result seems contradictory to in vitro study. One possible reason maybe that the formation of ES requires ERK activation only at the beginning of formation rather than during the entire process.

4.5.2 Sperm Release

Round spermatids develop into elongated sperm before final releasing.

Gonadotropin Regulated Testicular Helicase (GRTH/DDX25) is involved in this process, mainly by participating on the nuclear export and transport of specific mRNAs as well as the structural integrity of Chromatoid Bodies of round spermatids (154). As an RNA helicase and only DEAD-box family member regulated by androgen in spermatids, GRTH/DDX25 transcription in spermatid is regulated by AR signaling pathway in Sertoli cells through a paracrine fashion. Germ cell nuclear factor (GCNF) in spermatids can promote GRTH/DDX25 transcription and expression in response to androgen regulation (155–158). However, the signal relayed to spermatids remains to be further elucidated.

Before releasing sperm, SCs endocytose the residual body from maturing sperm. Kumar et al. found that AR dimerization can recruit corepressor nuclear receptor corepressor 1 (NCoR1) to the ARE of phosphatidylinositol binding clathrin assembly protein (Picalm) and early endosome antigen 1 (Eea1) and thereby inhibit their expression. Coactivator steroid receptor coactivator-1 (Src1) can be recruited to ARE of syntaxin 5 (Stx5a) and induce its expression (112, 159, 160). Since the products of these 3 genes are located around tubule bulbar complexes and participate in endocytosis and intracellular transport, it is possible that they are involved in residual body absorption.

Activation of Src is important for sperm release (161, 162). The injection of Src inhibitor into rat testis can block the release of elongating spermatids, while injection of an ERK inhibitor has little effect on sperm release (152, 163). Additionally, O’Donnell et al. pointed out that the disengagement complex, including αβ1 integrin which associates with Src, and tyrosine-phosphorylated focal adhesion kinase (FAK), remains associated with sperm that fail to be released. Both Src and FAK can be phosphorylated on activation of non-classical androgen signaling (149). Further study confirmed that activated non-classical signaling target Src is near the head of sperm to be released (164).

Also, sperm motility is significant during sperm release. Located in elongated spermatids, ATPase Ca++ transporting plasma membrane 4 (PMCA4) is critical for sperm motility (165). Recently, it was found that PMCA4 is positively regulated by AR signaling in SCs both in vitro and in vivo (121).

In a summary, non-classical AR signaling promotes Sertoli cell – Spermatid adhesion by activating both ERK and Src while promoting sperm release by activating Src. Considering the above study, future studies might focus on achieving a deeper understanding of the different effects of Src to immature spermatid and mature spermatid as well as the impact of both ERK and Src to other kinds of proteins in apical ES.

5 DISCUSSION ON ANDROGEN INSENSITIVITY SYNDROME: PRESENT ADVANCES AND FUTURE THERAPIES

Infertility is an emerging worldwide public health issue. Approximately 20-70% of cases are due to male infertility (166). For most men suffering from infertility, the primary cause is low quality and low quantity of sperm (167). Hormones, including androgens, are necessary for spermatogenesis. We have reviewed AR signaling in SCs above. Clinical mutations in androgen receptor can cause reproductive diseases such as Androgen insensitivity syndrome, Sertoli cell-only syndrome and
Obstructive azoospermia. Here we will focus on androgen insensitivity syndrome, which is closely related to AR mutations in SCs.

Androgen insensitivity syndrome (AIS) is an X-linked recessive disorder of sex development in patients with the 46, XY karyotype (168). According to the National Institutes of health, approximately 2-5 in 100000 people may have AIS. The biochemical mechanism behind AIS is the inability of cells expressing AR to respond to androgen, leading to incomplete or absent genital virilization of the 46, XY embryo (169). Specifically, the mutations in AR result in disrupted capacity of binding to testosterone or DHT, leading to impaired differentiation of the Wolffian ducts and impaired virilization of the external male genitalia respectively (170). At present, AIS is classified into two categories, AIS type I and AIS type II. In AIS type I, mutations exist in AR itself; this type of AIS can be clinically classified into complete AIS (CAIS), partial AIS (PAIS) and mild AIS (MAIS) according to the AR mutation level, while mutations in AIS type II occur in molecules downstream of AR rather than in AR itself (171). The clinical phenotype of CAIS is characterized by an external female phenotype with undescended testes (172), PAIS leads to different ranges of hypospadias and ambiguous genitalia (173) and individuals with MAIS display a male phenotype, sometimes with gynecomastia, and insufficient sperm production (174). Recent years, studies and many case reports have revealed different AR mutations in patients with AIS. Mutations found up to now include gene deletion, mutations in transactivation domain, mutations in the DNA binding domain, mutations in the ligand binding domain. (For additional information, please see review (175)) In addition, even individuals without a mutation in the AR gene can show an AIS-like syndrome, indicating that mutations may have occurred somewhere else (176).

Currently, researches on AIS focus mainly on recording patient phenotypes and detecting AR mutations through sequencing of AR gene. Various AR mutations have been found to date (177). Inadequate research on associated gene expression patterns presents much difficulties for the development of therapies, especially for type II AIS. In addition, few studies have used testicular histology to examine the effects of AR mutations on testis. Recently, one CAIS patient showed unusually high level of AMH and SOX9, accompanied by immature SCs, a phenomenon that has been linked in a mouse model to the AR/SOX9/AMH pathway discussed above (178). AMH, along with Inhibin B, which may have positive or inverse correlation with AMH, is thought to be appealing subject for study by endocrinologists because patients with androgen insensitivity or defects in androgen synthesis have normal or high levels of AMH (179).

Notably, a high level of estrogen was found in patients with CAIS, and this may explain the development of breast cancer in some of these patients. Supporting this idea, it is known that testosterone can be converted into estrogen via aromatase and luteinizing hormone can stimulate testicular estrogen synthesis. Researchers have found high levels of luteinizing hormone and testosterone in AIS patients (168, 175, 180). Interestingly, apolipoprotein D (APOD), which is induced by DHT, is a potential candidate marker for the detection of AIS, especially for type II AIS. Treating type II AIS patients with DHT can induce endogenous APOD expression but the level of APOD is below the calculated cut-off (181). Other molecular pathways downstream of AR in AIS patients are remaining to be elucidated. One question arises for our molecular research. Although mice and rats have high homology with humans, some phenotypes in AIS patients cannot be reproduced in mouse or rat models. Although this is a significant barrier in our research, we should not be pessimistic. In a comparison of control males and CAIS females, significant differences in the transcription levels of 612 genes were found at the cellular level, suggesting that androgens may play a role in transcriptome regulation in humans (182). We are pleased to see that AR can regulate the transcriptome level in mouse models (98); this observation can guide us to investigate genes with known function in mouse models in our clinical diagnosis and to research genes that show no overlap between two species in mice to determine their function.

In summary, our opinions are that the diagnosis for AIS should combine power from different fields of study. For geneticists, family history is recommended to record for prenatal diagnosis, along with determining the patient’s karyotype after birth (183). Some important biomarkers, such as AMH, estrogen, luteinizing hormone and testosterone should be measured at birth or at puberty to distinguish AIS from androgen synthesis deficiency by endocrinologists. Cytologists and histologists use fine needle aspiration cytology (184) and histopathology to examine the state of SCs and the testicular lumen, and the results obtained may be compared with results obtained from patients with other syndromes like, such as Sertoli cell-only syndrome or nonobstructive azoospermia, possibly benefiting from therapies for those diseases. Finding associated genes and impaired signaling pathway are tasks for molecular biologists. Combined efforts are powerful.

At present, the most common treatment for CAIS is gonadectomy in early adulthood. There are two reasons for this: 1) an undescended testis has an increased risk of malignant transformation after puberty; and 2) testosterone produced by the testis can be converted to estrogen, so puberty will occur naturally (185, 186). Besides, treatment for PAIS vary between different patients. Treatments currently include androgen supplementation at puberty, surgeries to repair hypospadias and bring undescended testes into the scrotum. Personal treatment should combine diagnosis, sex assignment and biochemical examination (187). Previous study using AR transgene model restored the impaired spermatogenesis in SC AR mutant mice (188). Whether transfection of AR constructs into human SCs can benefit AIS patients remains to be elucidated.

Moreover, the job of a doctor is not only to treat patients physically, but also to treat them psychologically. Helping AIS patients overcome their psychological disorders and live a normal life without discrimination is a responsible behavior for doctors and for society as a whole.

6 CONCLUSION AND PERSPECTIVE

Both classical and non-classical androgen receptor signaling pathway are essential for spermatogenesis. These two pathways
not only regulate genomic action in Sertoli cells but also influence germ cells between Sertoli cells through paracrine action. Sertoli cells are expected to be a new therapeutic target. However, rare studies focus on the relationship between androgen receptor signaling pathway, Sertoli cell and clinical diseases. The transgenic model developed recently which is able to activate only classical or non-classical signaling pathway, allows us to screen more genes related to androgen receptor signaling pathway. These genes are helpful for us to develop therapies for treating infertility. Moreover, spermatogonia transplantation is a method to inject spermatogonia into seminiferous tubule lumen and promote spermatogonia to form colonization at basement area, which may cure fertility fundamentally. The problem about making spermatogonia migrating from adluminal area to basement area may be solved by androgen therapies because lowering testicular testosterone level can open BTB reversibly.

REFERENCES

1. Agarwal A, Baskaran S, Parekh N, Cho C-L, Henkel R, Vij S, et al. Male Infertility. Lancet (2021) 397(10277):319–33. doi: 10.1016/s0140-6736(20)32667-2
2. Sharlip ID, Jarow JP, Belker AM, Lipshultz LI, Sigman M, Thomas AJ, et al. Best Practice Policies for Male Infertility. Fertil Steril (2001) 77(5):873–82. doi: 10.1016/s0015-0282(01)03105-9
3. Practice Committee of the American Society for Reproductive Medicine. Diagnostic Evaluation of the Infertile Male: A Committee Opinion. Fertil Steril (2015) 103(3):e18–25. doi: 10.1016/j.fertnstert.2014.12.103
4. de Kretser DM, Loveland KL, Meinhardt A, Simorangkir D, Wreford N. Androgen Receptor Signaling Pathway, Sertoli Cell and Clinical Diseases. The transgenic model developed recently which is able to activate only classical or non-classical signaling pathway, allows us to screen more genes related to androgen receptor signaling pathway. These genes are helpful for us to develop therapies for treating infertility. Moreover, spermatogonia transplantation is a method to inject spermatogonia into seminiferous tubule lumen and promote spermatogonia to form colonization at basement area, which may cure fertility fundamentally. The problem about making spermatogonia migrating from adluminal area to basement area may be solved by androgen therapies because lowering testicular testosterone level can open BTB reversibly.

AUTHOR CONTRIBUTIONS

J-MW, Z-FL, and W-XY conceived of and authored the paper. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported in part by National Natural Science Foundation of China (No 32072954).

ACKNOWLEDGMENTS

The authors want to show their appreciation to all members of the Sperm Laboratory in Zhejiang University for their support, encouragement, and assistance.
Wang et al.

Androgen Receptors in Sertoli Cells

27. Tan MH, Li J, Xu HE, Melcher K, Yong EL. Androgen Receptor: Structure, Role in Prostate Cancer and Drug Discovery. *Acta Pharmacol Sin* (2015) 36 (1):3–26. doi: 10.1038/aps.2014.18

28. Bremer WJ, Millar MR, Sharpe RM, Saunders PT. Immunohistochemical Localization of Androgen Receptors in the Rat Testis: Evidence for Stage-Dependent Expression and Regulation by Androgens. *Endocrinology* (1994) 135(3):1227–34. doi: 10.1210/endo.135.3.8070367

29. Suarez-Quian CA, Martinez-Garcia F, Nistal M, Regadera J. Androgen Receptor Distribution in Adult Human Testis. *J Clin Endocrinol Metab* (1999) 84(1):350–8. doi: 10.1210/jcem.84.1.5410

30. Smith LB, Walker WH. The Regulation of Spermatogenesis by Androgens. *Semin Cell Dev Biol* (2014) 30:2–13. doi: 10.1016/j.semcdb.2014.02.012

31. Swerdloff RS, Dudley RE, Page ST, Wang C, Salameh WA. Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels. *Endocr Rev* (2017) 38(3):220–54. doi: 10.1210/er.2016-1067

32. Shang Y, Myers M, Brown M. Formation of the Androgen Receptor: Structure, Selective Chromatin Binding and Transcriptional Regulation. *Mol Endocrinol* (2010) 24(5):898–913. doi: 10.1210/me.2009-0310

33. Saporita AJ, Zhang Q, Navai N, Dincer Z, Hahn J, Cai X, et al. Identification and Characterization of a Ligand-Regulated Nuclear Export Signal in Androgen Receptor. *J Biol Chem* (2003) 278(43):41998–2005. doi: 10.1074/jbc.M302460200

34. Denayer S, Helsen C, Thorrez L, Haelens A, Claessens F. The Rules of DNA Recognition by the Androgen Receptor. *Mol Endocrinol* (2010) 24(5):898–913. doi: 10.1210/me.2009-0310

35. Shah B, Pihlajamaa P, Dubois V, Kerkhofs S, Claessens F, Janne OA. Androgen Receptor Uses Relaxed Response Element Stringency for Selective Chromatin Binding and Transcriptional Regulation. *Vivo Nucleic Acids Res* (2014) 42(7):4230–40. doi: 10.1093/nar/gkt410

36. Källio P, Poukka H, Moilanen A, Janne OA, Palvimo JJ. Androgen Receptor-Mediated Transcriptional Regulation in the Absence of Direct Interaction With a Specific DNA Element. *Mol Endocrinol* (1995) 9 (9):1027–28. doi: 10.1210/mend.9.9.8747976

37. Heckert LL, Wilson EM, Nilson JH. Transcriptional Repression of the Alpha-Subunit Gene by Androgen Receptor Occurs Independently of DNA Binding But Requires the DNA-Binding and Ligand-Binding Domains of the Receptor. *Mol Endocrinol* (1997) 11(10):1497–506. doi: 10.1210/mend.11.10.9996

38. Fix C, Jordan C, Cano P, Walker WH. Testosterone Activates Mitogen-Activated Protein Kinase and the cAMP Response Element Binding Protein Transcription Factor in Sertoli Cells. *Proc Natl Acad Sci USA* (2004) 101 (30):10919–24. doi: 10.1073/pnas.0402478101

39. Deng Q, Wu Y, Zhang Z, Wang Y, Li M, Liang H, et al. Androgen Receptor Localizes to Plasma Membrane by Binding to Caveolin-1 in Mouse Sertoli Cells. *Int J Endocrinol* (2017) 2017:3985916. doi: 10.1155/2017/3985916

40. Cheng J, Watkins SC, Walker WH. Testosterone Activates Mitogen-Activated Protein Kinase via Src Kinase and the Epidermal Growth Factor Receptor in Sertoli Cells. *Endocrinology* (2007) 148(5):2066–74. doi: 10.1210/en.2006-1465

41. Deng Q, Zhang Z, Wu Y, Wu W-y, Zhang J, Jiang Z-M, et al. Non-Genomic Action of Androgens is Mediated by Rapid Phosphorylation and Regulation of Androgen Receptor Trafficking. *Cell Physiol Biochem* (2017) 43(1):223–36. doi: 10.1159/000460343

42. Toocheck C, Cistler T, Shupe J, Crum C, Ravindranathan P, Lee TK, et al. Mouse Spermatogenesis Requires Classical and Nonclassical Testosterone Signaling. *Biol Reprod* (2016) 94(1):11. doi: 10.1095/biolreprod.115.132068

43. Lieberherr M, Grosse B. Androgens Increase Intracellular Calcium Concentration and Inositol 1,4,5-Trisphosphate and Dicacylglycerol Formation via a Pertussis Toxin-Sensitive G Protein. *J Biol Chem* (1994) 269(10):7217–23. doi: 10.1074/jbc.269.10.7217

44. Von Ledebur EL, Almeida JP, Loss ES, Wassermann GF. Rapid Effect of Testosterone on Rat Sertoli Cell Membrane Potential. Relationship With K+ATP Channels. *Horm Metab Res = Hormon- und Stoffwechselforschung = Horm Metabol* (2002) 34(10):550–5. doi: 10.1055/s-2002-35426

45. Loss ES, Jacobsen M, Costa ZS, Jacobus AP, Borelli F, Wassermann GF. Testosterone Modulates K+–ATP Channels in Sertoli Cell Membrane via the PLC·PIP2 Pathway. *Horm Metab Res = Hormon- und Stoffwechselforschung = Horm Metabol* (2004) 36(6):519–25. doi: 10.1055/s-2004-285753

46. O'Shaughnessy PJ, Monteiro A, Abel M. Testicular Development in Mice Lacking Receptors for Follicle Stimulating Hormone and Androgen. *PloS One* (2012) 7(4):e35136. doi: 10.1371/journal.pone.0035136

47. Tan KA, Turner JK, Sanders PT, Verhoeven G, De Gendt K, Atanassova N, et al. Androgen Regulation of Stage-Dependent Cyclin D2 Expression in Sertoli Cells Suggests a Role in Modulating Androgen Action on Spermatogenesis. *Biol Reprod* (2005) 72(5):1151–60. doi: 10.1095/biolreprod.104.037689

48. Johnston H, Baker PJ, Abel M, Charlton HM, Jackson G, Fleming L, et al. Regulation of Sertoli Cell Number and Activity by Follicle-Stimulating Hormone and Androgen During Postnatal Development in the Mouse. *Endocrinology* (2004) 145(1):318–29. doi: 10.1210/endo.2003-1055

49. Hu S, Liu D, Liu S, Li C, Guo J, Lycium Barbarum Polysaccharide Ameliorates Heat-Stress-Induced Impairment of Primary Sertoli Cells and the Blood-Testis Barrier in Rat via Androgen Receptor and Akt Phosphorylation. *Evid Based Complement Alternat Med* (2021) 2021:5574202. doi: 10.1155/2021/5574202

50. Edelstein NY, Rey RA. Importance of the Androgen Receptor Signaling in Gene Transactivation and Transregression for Pubertal Maturation of the Testis. *Cells* (2018) 7(8):861. doi: 10.3390/cells7080861

51. Shah W, Khan R, Shah B, Khan A, Di S, Liu W, et al. The Molecular Mechanism of Sex Hormones on Sertoli Cell Development and Proliferation. *Front Endocrinol (Lausanne)* (2021) 12:648141. doi: 10.3389/fendo.2021.648141

52. Martins AD, Alves MG, Simões VL, Dias TR, Rato L, Moreira PL, et al. Control of Sertoli Cell Metabolism by Sex Steroid Hormones Is Mediated Through Modulation in Glycolysis-Related Transporters and Enzymes. *Cell Tissue Res* (2013) 354(3):861–8. doi: 10.1007/s00441-013-1722-7

53. Berger T. Testicular Estradiol and the Pattern of Sertoli Cell Proliferation in Prepuberal Bulls. *Theriogenology* (2019) 136:60–5. doi: 10.1016/j.theriogenology.2019.06.031

54. Krzanowska H, Bilinska B. Number of Chromocentres in the Nuclei of Mouse Sertoli Cells in Relation to the Strain and Age of Males From Puberty to Senescence. *J Reprod Fertil* (2011) 108(2):343–50. doi: 10.1530/jrf.0.1180343
Itman C, Wong C, Hunyadi B, Ernst M, Jans DA, Loveland KL. Smad3

Hazra R, Upton D, Desai R, Noori O, Jimenez M, Handelsman DJ, et al.

De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S,

Chojnacka K, Brehm R, Weider K, Hejmej A, Lydka M, Kopera-Sobota I,

Lasala C, Schteingart HF, Arouche N, Bedecarra

Wang G, Weng CC, Shao SH, Zhou W, de Gendt K, Braun RE, et al.

Shan LX, Bardin CW, Hardy MP. Immunohistochemical Analysis of

Josso N, Rey RA. What Does AMH Tell Us in Pediatric Disorders of Sex

da Rosa LA, Escott GM, Simonetti RB, da Silva JCD, Werlang ICR, Goldani

Lasala C, Schteingart HF, Arouche N, Bedecarra

69. Wang G, Weng CC, Shao SH, Zhou W, de Gendt K, Braun RE, et al.

68. Wang G, Weng CC, Shao SH, Zhou W, de Gendt K, Braun RE, et al.

67. Wang G, Weng CC, Shao SH, Zhou W, de Gendt K, Braun RE, et al.

66. Lasala C, Schteingart HF, Arouche N, Bedecarra

65. da Rosa LA, Escott GM, Simonetti RB, da Silva JCD, Werlang ICR, Goldani

64. Josso N, Rey RA. What Does AMH Tell Us in Pediatric Disorders of Sex

63. Shan LX, Bardin CW, Hardy MP. Immunohistochemical Analysis of

62. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S,

61. Chojnacka K, Brehm R, Weider K, Hejmej A, Lydka M, Kopera-Sobota I,

60. Wang G, Weng CC, Shao SH, Zhou W, de Gendt K, Braun RE, et al.

59. Itman C, Wong C, Hunyadi B, Ernst M, Jans DA, Loveland KL. Smad3

58. Lan KC, Chen YT, Chang C, Chang YC, Lin HJ, Huang KE, et al. Up-

57. Hazra R, Upton D, Desai R, Noori O, Jimenez M, Handelsman DJ, et al.

56. Lasala C, Schteingart HF, Arouche N, Bedecarra

55. Wang G, Weng CC, Shao SH, Zhou W, de Gendt K, Braun RE, et al.

54. Hazra R, Upton D, Desai R, Noori O, Jimenez M, Handelsman DJ, et al.

53. Wang G, Weng CC, Shao SH, Zhou W, de Gendt K, Braun RE, et al.

52. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

51. Chojnacka K, Brehm R, Weider K, Hejmej A, Lydka M, Kopera-Sobota I, 

50. Itman C, Wong C, Hunyadi B, Ernst M, Jans DA, Loveland KL. Smad3

49. Hazra R, Upton D, Desai R, Noori O, Jimenez M, Handelsman DJ, et al.

48. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

47. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

46. Hazra R, Upton D, Desai R, Noori O, Jimenez M, Handelsman DJ, et al.

45. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

44. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

43. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

42. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

41. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

40. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

39. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

38. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

37. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

36. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

35. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

34. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

33. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

32. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

31. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

30. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

29. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

28. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

27. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

26. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

25. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

24. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

23. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

22. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

21. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

20. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

19. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

18. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

17. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

16. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

15. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

14. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

13. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

12. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

11. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

10. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

9. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

8. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

7. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

6. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

5. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

4. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

3. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

2. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

1. De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, 

Wang et al. Androgen Receptors in Sertoli Cells

99. Stanton PG, Sluka P, Foo CF, Stephens AN, Smith AI, McLachlan RI, et al. Proteomic Changes in Rat Spermatogenesis in Response to In Vivo Androgen Manipulation: Impact on Meiotic Cells. PloS One (2012) 7(7):e41718. doi: 10.1371/journal.pone.0041718

100. Yang L, Wang Y, Zhang Q, Lai Y, Li C, Zhang Q, et al. Identification of Hsf1 as a Novel Androgen Receptor-Regulated Gene in Mouse Sertoli Cells. Mol Reprod Dev (2014) 81(6):514–23. doi: 10.1002/mrd.22318

101. Hu Z, Shanker S, MacLean JA2nd, Ackerman SL, Wilkinson MF. The RHOX3 Homeodomain Protein Mediates Transcriptional Repression of the Ntrn-1 Receptor Gene UncSc. J Biol Chem (2008) 283(7):3866–76. doi: 10.1074/jbc.M706717200

102. Lindsey JS, Wilkinson MF. Pem: A Testosterone- and LH-Regulated Homeobox Gene Expressed in Mouse Sertoli Cells and Epididymis. Dev Biol (1996) 179(2):471–84. doi: 10.1006/dbio.1996.0276

103. Bhawardj A, Sohni A, Lou CH, De Gendt K, Zhang F, Kim E, et al. Concordant Androgen-Regulated Expression of Divergent RhoX5 Promoters in Sertoli Cells. Endocrinology (2022) 163(1):1–17. doi: 10.1210/endoc/bqb237

104. Camara ML, Almeida TB, de Santi F, Rodrigues BM, Cerri PS, Beltrame FL, et al. Fluoxetine-Induced Androgenic Failure Impairs the Seminiferous Tubules Integrity and Increases Ubiquitin Carboxyl-Terminal Hydrolyase L1 (UCHL1): Possible Androgenic Control of UCHL1 in Germ Cell Death? Biomed Pharmacother = Biomed Pharmacother (2019) 119:1126–39. doi: 10.1016/j.biopha.2019.04.034

105. Elliott MR, Zheng S, Park D, Woodson RL, Reardon MA, Juncadella JJ, et al. Unexpected Requirement for ELMO1 in Cleavage of Apoptotic Germ Cells In Vivo. Nature (2010) 467(7313):333–7. doi: 10.1038/nature09356

106. Wu RC, Jiang M, Beaudet AL, Wu MY. ARID4A and ARID4B Regulate Male Fertility, a Functional Link to the AR and RB Pathways. Proc Natl Acad Sci USA (2013) 110(12):4616–21. doi: 10.1073/pnas.1218311103

107. Wu RC, Zeng Y, Pan IW, Wu MY. Androgen Receptor Coactivator ARID4B Is Required for the Function of Sertoli Cells in Spermatogenesis. Mol Endocrinol (2015) 29(9):1334–46. doi: 10.1210/me.2015-1089

108. Domanskyi A, Zhang FP, Nurmio M, Palvimo JJ, Toppari J, Janne OA. Type I DnaJ Homolog, DjA1, Regulates Androgen Receptor Signaling and Gene in Sertoli Cells Isolated From Testes of Adult Rats. Endocrinology (2004) 145(2):781–9. doi: 10.1210/en.2003-0987

109. Zhao Z, Qiao L, Dai Z, He Q, Lan X, Huang S, et al. LncNONO-AS regulates AR expression by mediating NONO. Theriogenology (2020) 145:198–206. doi: 10.1016/j.theriogenology.2019.10.025

110. Gonzalez-Herrera IG, Prado-Loquero L, Pileur F, Conte C, Morin A, Cabon F, et al. Testosterone regulates FGF-2 expression during testis maturation by an IRES-Dependent translational mechanism. FASEB J (2006) 20(3):476–8. doi: 10.1096/fj.04-3314fe

111. Geng Q, Ni LW, Ouyang B, Hu YH, Zhao Y, Guo J. Alamine and Arginine Rich Domain Containing Protein, Aard, Is Directly Regulated by Androgen Receptor in Mouse Sertoli Cells. Mol Med Rep (2017) 15(1):352–8. doi: 10.3892/mmr.2016.6028

112. El Chami N, Ikhlief F, Kaszas K, Yakoub S, Tabene O, Siddeek B, et al. Androgen-Dependent Apoptosis in Male Germ Cells is Regulated Through the Proto-Oncoprotein CB1. J Cell Biol (2005) 171(4):651–6. doi: 10.1083/jcb.200507076

113. Sun R, Liang H, Guo H, Wang Z, Deng Q. PMCA4 Gene Expression is Regulated by the Androgen Receptor in the Mouse Testis During Spermatogenesis. Mol Med Rep (2021) 23(2):152. doi: 10.3892/mmr.2020.11791

114. Silva EJ, Patrao MT, Tsutira JK, O’Rang MG, Avellar MC. Epimydlal Protease Inhibitor (EPUP) is Differentially Expressed in the Male Rat Reproductive Tract and Immunolocalized in Maturing Spermatozoa. Mol Reprod Dev (2012) 79(12):832–42. doi: 10.1002/mrd.22119

115. Kuwahara S, Ikei A, Taguchi Y, Tabuchi Y, Fujimoto N, Obinata M, et al. RHOX5 Homeodomain Protein Mediates Transcriptional Repression of the Proto-Oncoprotein Cbl. J Biol Chem (2017) 292(20):15243–50. doi: 10.1074/jbc.e117.789302

116. Eacker SM, Shima JE, Connolly CM, Sharma M, Holdcraft RW, Griswold MD, et al. Transcriptional Profiling of Androgen Receptor (AR) Mutants Suggests Instructive and Permissive Roles of AR Signaling in Germ Cell Development. Mol Endocrinol (2007) 21(4):895–907. doi: 10.1210/me.2006-0113

117. Van HH, Mruk DD, Lee WM, Cheng CY. Blood-Testis Barrier Dynamics are Regulated by Testosterone and Cytokines via Their Differential Effects on the Kinetics of Protein Endocytosis and Recycling in Sertoli Cells. FASEB J (2008) 22(6):1945–59. doi: 10.1096/fj.06-070342

118. Meng J, Greenlee AR, Taub CJ, Braun RE. Sertoli Cell-Specific Deletion of the Androgen Receptor Compromises Testicular Immune Privilege in Mice. Biol Reprod (2011) 85(2):254–60. doi: 10.1095/biolreprod.110.089621

119. Li MW, Xia W, Mruk DD, Wang CQ, Yan HH, Siu MK, et al. Tumor Necrosis Factor (Alpha) Reversibly Disrupts the Blood-Testis Barrier and Impairs Sertoli-Germ Cell Adhesion in the Seminiferous Ephithelium of Adult Rat Testes. J Endocrinol (2006) 190(2):313–29. doi: 10.1677/joe.0,016778

120. Meng J, Holdcraft RW, Shima JE, Griswold MD, Braun RE. Androgens Regulate the Permeability of the Blood-Testis Barrier. Proc Natl Acad Sci USA (2005) 102(46):16696–700. doi: 10.1073/pnas.0508041102

121. Kaitu’u-Lino TJ, Sluka P, Foo CF, Stanton PG. Claspin-Induced Stabilisation and Localisation is Regulated by Androgens in Rat Sertoli Cells In Vitro. Reproduction (2007) 133(6):1169–79. doi: 10.1530/REP-06-0385

122. Chakraborty P, William Buaas F, Sharma M, Smith BE, Greenlee AR, Eacker SM, et al. Androgen-Dependent Sertoli Cell Tight Junction Remodeling is Mediated by Multiple Tight Junction Components. Mol Endocrinol (2014) 28(7):1055–72. doi: 10.1210/me.2013-1134

123. Denolet A, De Gendt K, Allemeersch J, Engelen K, Marchal K, Van Hummelen P, et al. The Effect of a Sertoli Cell-Selective Knockout of the Androgen Receptor on Testicular Gene Expression in Prepubertal Mice. Mol Endocrinol (2006) 20(2):321–34. doi: 10.1210/en.2005-00113

124. Wang RS, Ye H, Chen LM, Lin HY, Zhao H, Ni J, et al. Androgen Receptor in Sertoli Cell is Essential for Germ Cell Nursing and Juncational Complex Formation in Mouse Testes. Endocrinology (2006) 147(12):5624–33. doi: 10.1210/en.2006-0138

125. Traweger A, Fuchs R, Krizbai IA, Weiger TM, Bauer HC, Bauer H. The Tight Junction Protein ZO-2 Localizes to the Nucleus and Interacts With the Heterogeneous Nuclear Ribonucleoprotein Scaffold Attachment Factor-B. J Biol Chem (2003) 278(4):2692–700. doi: 10.1074/jbc.M206821200

126. Guo J, Shi YQ, Yang W, Li YC, Hu ZY, Liu XY. Testosterone Upregulation of Tissue Type Plasminogen Activator Expression in Sertoli Cells: tPA Expression in Sertoli Cells. Endocrine (2007) 32(1):83–9. doi: 10.1007/s12020-007-9014-1

127. Gunnarsson M, Lecander I, Abrahamsson PA. Factors of the Plasminogen Activator System in Human Testis, as Demonstrated by in-Situ
Hybridization and Immunohistochemistry. Mol Hum Reprod (1999) 5 (10):934–40. doi: 10.1093/molehr/5.10.934
133. Dieter RH, Shihan M, Stammler A, Konrad L, Scheiner-Bobis G. Cardiostatic Steroid Ouabain Stimulates Expression of Blood-Testis Barrier Proteins Claudin-1 and -11 and Formation of Tight Junctions in Sertoli Cells. Mol Cell Endocrinol (2015) 405:1–13. doi: 10.1016/j.mce.2015.02.004
134. Papadopoulos D, Dieter R, Shihan M, Kirch U, Scheiner-Bobis G. Dehydroepiandrosterone Sulfate Stimulates Expression of Blood-Testis Barrier Proteins Claudin-3 and -5 and Tight Junction Formation via a Gnaq/Gap11-Coupled Receptor in Sertoli Cells. PLoS One (2016) 11(3): e0150143. doi: 10.1371/journal.pone.0150143
135. Li XX, Chen SR, Shen B, Yang JL, Ji SY, Wen Q, et al. The Heat-Induced Reversible Change in the Blood-Testis Barrier (BTB) Is Regulated by the Androgen Receptor (AR) via the Partitioning-Defective Protein (Par) Polarity Complex in the Mouse. Biol Reprod (2013) 89(1):12. doi: 10.1095/ bioreprod.111.109405
136. Kopera I, Durlej M, Hajmjej A, Knapczyk-Stwora K, Duda M, Slomczyńska M, et al. Differential Expression of Connexin 43 in Adult Pig Testes During Normal Spermatogenic Cycle and After Flutamide Treatment. Reprod Domest Anim (2011) 46(6):1050–60. doi: 10.1111/j.1439-1635.2011.01783.x
137. Xia Q, Zhang D, Wang J, Zhang X, Song W, Chen R, et al. Andrograph Indirectly Regulates Gap Junction Component Connexin 43 Through Wilms Tumor-1 in Sertoli Cells. Stem Cells Dev (2020) 29(3):169–76. doi: 10.1089/ stem.2019.07.0186
138. RajamaniakGM, Kastelic JP, Thundt JL. The Ubiquitous Isoform of Na/K-ATPase (ATP1A1) Regulates Junctional Proteins, Connexin 43 and Claudin 11 via Src-EGFR-ERK1/2-CREB Pathway in Rat Sertoli Cells. Biol Reprod (2017) 96(2):456–68. doi: 10.1095/bioreprod.116.141267
139. McCabe MJ, Allan CM, Foo CF, Nicholls PK, McCavish KJ, Stanton PG. Androgen Initiates Sertoli Cell Tight Junction Formation in the Hypogonadal (Hpg) Mouse. Biol Reprod (2012) 87(2):38. doi: 10.1095/ bioreprod.111.094318
140. Mruk DD, Cheng CY. The Mammalian Blood-Testis Barrier: Its Biology and Regulation. Endocr Rev (2015) 36(5):564–91. doi: 10.1210/er.2014-1101
141. Bruzewer M, Uetch M, Ivanov AI, Hopkins AM, Parkos CA, Nusrat A. Interferon-Gamma Induces Internalization of Epithelial Tight Junction Proteins via a Macropinocytosis-Like Process. FASEB J (2005) 19(8):923–33. doi: 10.1096/fj.04-3260com
142. Shen L, Turner JR. Actin Depolymerization Disrupts Tight Junctions via Caveolin-Mediated Endocytosis. Mol Biol Cell (2005) 16(9):3919–36. doi: 10.1091/mbc.e04-12-1089
143. Su L, Mruk DD, Lee WM, Cheng CY. Differential Effects of Testosterone and TGF-β3 on Endocytic Vesicle-Mediated Protein Trafficking Events at the Blood-Testis Barrier. Exp Cell Res (2010) 316(17):2945–60. doi: 10.1016/j.yexcr.2010.07.018
144. Yin L, Lu L, Lin X, Wang X. Crucial Role of Androgen Receptor in Resistance and Endurance Trainings-Induced Muscle Hypertrophy Through IFG-1/ IFG-1r- PI3K/Akt- mTOR Pathway. Nutr Metab (Lond) (2020) 17:26. doi: 10.1186/s12986-020-00446-y
145. Wei Y, Zhou Y, Long C, Wu H, Hong Y, Fu Y, et al. Polystyrene Microplastics Disrupt the Blood-Testis Barrier Integrity Through ROS-Mediated Inbalance of Mtorc1 and Mtorc2. Environ Pollut (2021) 289:117904. doi: 10.1016/j.envpol.2021.117904
146. McLachlan RI, Wreford NG, O’Donnell L, de Kretser DM, Robertson DM. The Endocrine Regulation of Spermatogenesis: Independent Roles for Androgen Receptor (AR) and the Partitioning-Defective Protein (Par). Mol Cell Endocrinol (1996) 141(1):1–9. doi: 10.1016/ j.mce.1480001
147. Beardsley A, O’Donnell L. Characterization of Normal Spermatiation and Spermiogenesis Failure Induced by Hormone Suppression in Adult Rats. Biol Reprod (2003) 68(4):1299–307. doi: 10.1095/bioreprod.102.009811
148. Holdcroft RW, Braun RE. Androgen Receptor Function is Required in Sertoli Cells for the Terminal Differentiation of Haloploid Spermatids. Development (2004) 131(2):459–67. doi: 10.1242/dev.00957
149. Walker WH. Non-Classical Actions of Testosterone and Spermatogenesis. Philos Trans R Soc Lond B Biol Sci (2010) 365(1546):1557–69. doi: 10.1098/ rstb.2009.0258
150. Shupe J, Cheng J, Puri P, Kostereva N, Walker WH. Regulation of Sertoli- Germ Cell Adhesion and Sperm Release by FSH and Nonclassical Testosterone Signaling. Mol Endocrinol (2011) 25(2):238–52. doi: 10.1210/ me.2010-0030
151. Zhang J, Wong CH, Xia W, Mruk DD, Lee NP, Lee WM, et al. Regulation of Sertoli Cell Adhesions Junction Dynamics via Changes in Protein-Protein Interactions of the N-Cadherin-Beta-Catenin Protein Complex Which are Possibly Mediated by C-Src and Myotubulin-Related Protein 2: An In Vivo Study Using an Androgen Suppression Model. Endocrinology (2005) 146(12):1268–84. doi: 10.1210/en.2004-1194
152. Dufau ML, Kavarthapu R. Gonadotropin Regulation Testicular RNA Helicase, Two Decades of Studies on Its Structure Function and Regulation From Its Discovery Opens a Window for Development of a Non-Hormonal Oral Male Contraceptive. Front Endocrinol (Lausanne) (2019) 10:576. doi: 10.3389/fendo.2019.00576
153. Wang et al. Androgen Receptors in Sertoli Cells
170. Veyssiere G, Berger M, Jean-Faucher C, de Turkheim M, Jean C. Testosterone and Dihydrotosterone in Sexual Ducts and Genital Tubercle of Rabbit Fetuses During Sexual Organogenesis: Effects of Fetal Decapitation. J Steroid Biochem (1982) 17(2):149–54. doi: 10.1016/0022-4731(82)90114-5

171. Adachi M, Takayanagi R, Tomura A, Imasaki K, Kato S, Goto K, et al. Androgen-Insensitivity Syndrome as a Possible Coactivator Disease. N Engl J Med (2000) 343(12):856–62. doi: 10.1056/nejm200009213431205

172. Oakes MB, Eyvazzadeh AD, Quint E, Smith YR. Complete Androgen Insensitivity Syndrome—a Review. J Pediatr Adolesc Gynecol (2008) 21(6):305–10. doi: 10.1016/j.jpag.2007.09.006

173. Hellmann P, Christiansen P, Johannsen TH, Main KM, Duno M, Juul A. Male Patients With Partial Androgen Insensitivity Syndrome: A Longitudinal Follow-Up of Growth, Reproductive Hormones and the Development of Gynaecomastia. Arch Dis Child (2012) 97(5):403–9. doi: 10.1136/archdischild-2011-300584

174. Hage M, Drui D, Francou B, Mercier S, Guiochon-Mantel A, Belaisch-Allart J, et al. Structural Analysis of the Impact of a Novel Androgen Receptor Gene Mutation in Two Adult Patients With Mild Androgen Insensitivity Syndrome. Andrologia (2021) 53(1):e13865. doi: 10.1111/and.13865

175. Gulıa C, Baldassarra S, Zangari A, Briganti V, Gigli S, Gafi M, et al. Androgen Insensitivity Syndrome. Eur Rev Med Pharmacol Sci (2018) 22(12):3873–87. doi: 10.26355/eurrev_201806_15272

176. Deeb A, Mason C, Lee YS, Hughes IA. Correlation Between Genotype, Phenotype and Sex of Rearing in 111 Patients With Partial Androgen Insensitivity Syndrome. Clin Endocrinol (2005) 63(1):56–62. doi: 10.1111/j.1365-2265.2005.02298.x

177. Gottlieb B, Lehvaslaiho H, Beitel LK, Lumbroso R, Pinsky L, Trifiro M. The Androgen Receptor Gene Mutations Database. Nucleic Acids Res (1998) 26(1):234–8. doi: 10.1093/nar/26.1.234

178. Bukhari I, Li G, Wang L, Iqbal F, Zhang H, Zhu J, et al. Effects of Androgen Receptor Mutation on Testicular Histopathology of Patient Having Complete Androgen Insensitivity. J Mol Histol (2017) 48(3):159–67. doi: 10.1007/s12033-017-9714-7

179. Cortes D, Clasen-Linde E, Hutson JM, Li R, Thorup J. The Sertoli Cell Hormones Inhibin-B and Anti Mullerian Hormone Have Different Patterns of Secretion in Prepubertal Cryptorchid Boys. J Pediatr Surg (2016) 51(3):e745–80. doi: 10.1016/j.jpedsurg.2015.08.059

180. Schweikert HU, Milewich L, Wilson JD. Aromatization of Androstenedione by Cultured Human Fibroblasts. J Clin Endocrinol Metab (1976) 43(4):785–95. doi: 10.1210/jcem-43-4-785

181. Appari M, Werner R, Wunsch L, Cario G, Demeter J, Hiort O, et al. Apolipoprotein D (APOD) Is a Putative Biomarker of Androgen Receptor Function in Androgen Insensitivity Syndrome. J Mol Med (Berl) (2009) 87(6):623–32. doi: 10.1007/s00109-009-0462-3

182. Holterhus PM, Deppe U, Werner R, Reuter-Unrath A, Bebermeier JH, Wunsch L, et al. Intracrine Androgen-Dependent Gene Expression Patterns Revealed by Comparison of Genital Fibroblasts From Normal Males and Individuals With Complete and Partial Androgen Insensitivity Syndrome. BMC Genomics (2007) 8:376. doi: 10.1186/1471-2164-8-376

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wang, Li and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
| Term | Definition |
|------|------------|
| 11-KT | 11-ketotestosterone |
| Aard | Alanine and arginine rich domain |
| AIS | Androgen insensitive syndrome |
| AMH | Anti Mullerian hormone |
| APOD | Apolipoprotein D |
| ARE | Androgen response element |
| ARID4A/4B | AT-rich interaction domain 4A/4B |
| ARIP4 | Androgen receptor-interacting protein 4 |
| ARKO | Androgen receptor knock out |
| BTB | Blood-testis barrier |
| CAIS | Complete androgen insensitive syndrome |
| Cbl | Ccalcineurin B-like protein |
| CK18 | Cytokeratin 18 |
| CRE | cAMP-response element |
| CREB | cAMP-response element-binding protein |
| Cx43 | Connexin 43 |
| DHT | Dihydrotestosterone |
| Dja1 | Type 1 DnaJ protein |
| DSBs | DNA double strand breaks |
| Eea1 | Early endosome antigen 1 |
| EGFR | Epidermal growth factor receptor |
| Elm1 | Engagement and cell motility 1 |
| ES | Extracellular matrix specialization |
| FAK | Focal adhesion kinase |
| FGFR | Fibroblast growth factor 2 |
| GATA-2 | GATA binding protein 2 |
| GC | Germ cell |
| GCNF | Germ cell nuclear factor |
| GDNF | GDNF-derived neurotrophic factor |
| GJ | Gap junction |
| GpI | Glycosylphosphatidylinositol |
| Gnrh/ddx25 | Gonadotropin regulated testicular helicase |
| hpg | Hypogonadal |
| Igf3 | Insulin like growth factor 3 |
| Hsf1 | Heat shock transcription factor 1 |
| IncNONO-AS | Target NONO IncRNA |
| MAIS | Mild androgen insensitive syndrome |
| NASP | Nuclear autoantigenic sperm protein |
| Ncor1 | Nuclear receptor corepressor 1 |
| Nrg1 | Neuregulin 1 |
| NONO | Non-POU domain-containing octamer-binding protein |
| p90RSK | Ribosomal protein S6 kinase A1 |
| PAIS | Partial androgen insensitive syndrome |
| PGF2 | Prostaglandin E2 |
| p38 | Phosphatidylinositol 3 kinase |
| Piam | Phosphatidylinositol binding clathrin assembly protein |
| Pdx | Promyelocytic leukemia zinc finger |
| PMCA4 | ATPase Ca** transporting plasma membrane 4 |
| Rhox5 | Paraspeckle component 1 |
| Rnf4 | Really interesting new gene (RING) finger protein 4 |
| SC | Sertoli cell |
| SCARKO | Sertoli cell androgen receptor knock out |
| SF1 | Steroidogenic factor 1 |
| Sfpq | Splicing factor proline/glutamine rich |
| Sox9 | Sex determining region Y-box 9 |
| Spen | Epithelial myocyte-specific inhibitor |
| Src | SRC proto-oncogene |
| Src1 | Steroid receptor coactivator-1 |
| SSC | Spermatozoa stem cell |
| Sx5a | Syntaphilin 5 |
| T | Testosterone |
| TE | Testosterone and oestradiol |
| Tm | Testicular feminized mouse |
| Tpa | Type plasmaphrenogen activator |
| TJ | Tight junction |
| Tram1 | Thyroid hormone receptor activator molecule-1 |
| Tubb3 | Class I1 tubulin |
| Tzp | Testis zinc finger protein |
| Ube2b | Ubiquitin-conjugating enzyme E2B |
| Uch1 | Ubiquitin carboxy-terminal hydrolase L1 |
| Unc5c | Unc-5 Netrin receptor C(UNC5C) |
| Wnt5a | Wingless-type MMTV Integration Site Family Member 5A |
| Wt1 | WT1 transcription factor |
| Zif9 | Zif-1 and Irf-1 like protein 9 |